Melanotan I
Melanotan I (Afamelanotide)
The first-generation melanocortin analog developed for tanning and erythropoietic protoporphyria. Afamelanotide is FDA-approved under the brand name Scenesse.
Typical Cost
$15,000-20,000/year (Scenesse)
Status
Research
Peptide Profile
Melanotan I
Mechanism of Action
Activates melanocortin-1 receptors to stimulate melanin production. Longer half-life than Melanotan II with more gradual tanning effects and fewer side effects.
Common Dosages
subcutaneous implant
16mg
Every 60 days · Ongoing
Benefits
FDA-approved indication
Melanoma prevention in EPP
Gradual natural-looking tan
Fewer side effects than MT2
Long-acting implant
Side Effects
Nausea (less than MT2)
Facial flushing
Appetite changes
Implant site reactions
Key Research
Scenesse FDA approval for EPP
FDA approved for prevention of phototoxic reactions in EPP
Regulatory Status
FDA-approved as Scenesse for erythropoietic protoporphyria. Not approved for cosmetic tanning.
Contraindications
- ⚠History of melanoma
- ⚠Active skin cancer
- ⚠Pregnancy/breastfeeding
Not directly relevant to GLP-1 users. FDA-approved for specific medical condition only.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.